← Back

Wire · opportunities

Expanding Ovarian Cancer Testing in South Africa

Published

19 November 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

South Africa

◆ Source

Read at borgenproject.org →

◆ Verified

Fusion42 · 20 November 2026 · Fusion42 review

The Helix Project, launched by AstraZeneca in South Africa, aims to expand access to advanced ovarian cancer genetic testing (HRD testing) through international collaboration to lower costs and enable earlier diagnosis. This initiative targets a country where 84.5% of the population lacks private healthcare, ovarian cancer diagnoses are rising sharply, and most cases are detected late with high mortality rates.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You now have a clearer entry into South Africa’s ovarian cancer testing market through AstraZeneca’s new project lowering costs and speeding diagnosis. This opens a pathway to serve a largely uninsured, underserved population with urgent demand for early cancer detection.

◆ Coverage

1 source · 19 Nov 2026

◆ Related on Wire

◆ Topics

Medtechovarian-cancergenetic-testinghealthcare-accesscost-reductionAstraZenecaSouth-Africa